Last $3.12 HKD
Change Today -0.07 / -2.19%
Volume 284.0K
1061 On Other Exchanges
Hong Kong
As of 4:01 AM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

essex bio-technology ltd (1061) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $3.88
52 Week Low
09/17/13 - $1.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ESSEX BIO-TECHNOLOGY LTD (1061)

Related News

No related news articles were found.

essex bio-technology ltd (1061) Related Businessweek News

No Related Businessweek News Found

essex bio-technology ltd (1061) Details

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biopharmaceutical products for the treatment and healing of surface wounds and eye wounds in the People’s Republic of China. The company is also involved in the research and development of basic fibroblast growth factor products for new indications, as well as other ophthalmic pharmaceutical projects; and marketing and distribution of biopharmaceutical products. Its products include Beifushu eye drops and eye gel that enhances corneal reparation and corneal wound healing; and Beifuji spray, Beifuji Lyophilized powder, and Beifuxin gel to treat burn and scald wounds, acute wounds, surgical incisions, chronic wounds, and skin grafting, as well as for use in other applications. The company’s products also comprise Diclofenac Sodium eye drops for treating uveitis keratitis and scleritis, and controlling corneal neovascularization; inflammation caused by ocular operation, laser trabeculoplasty, and various ocular injuries; pain and inflammation after photorefractive keratectomy; and allergic ocular diseases, such as spring conjunctivitis and seasonal allergic conjunctivitis, as well as for pupillary responses during cataract surgery. Its Diclofenac Sodium eye drops are also used in treating and preventing inflammation after cataract surgery and intraocular lens procedures, as well as cystoid macular edema; and for accelerating the formation of filtering bleb after glaucoma filtering surgery. The company was incorporated in 2000 and is headquartered in Zhuhai, the People’s Republic of China.

651 Employees
Last Reported Date: 08/11/14
Founded in 2000

essex bio-technology ltd (1061) Top Compensated Officers

Managing Director, General Manager and Execut...
Total Annual Compensation: $1.0M
Founder, Chairman, Member of Nomination Commi...
Total Annual Compensation: $1.2M
Compliance Officer, Executive Director and Me...
Total Annual Compensation: $909.7K
Compensation as of Fiscal Year 2013.

essex bio-technology ltd (1061) Key Developments

Essex Bio-Technology Ltd. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Essex Bio-Technology Ltd. announced unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported turnover of HKD 231,332,000 against HKD 165,150,000 a year ago. Profit before income tax expense was HKD 37,363,000 against HKD 35,482,000 a year ago. Profit for the period was HKD 30,588,000 against HKD 26,873,000 a year ago. Profit attributable to owners of the company was HKD 30,588,000 against HKD 26,873,000 a year ago. Basic and diluted earnings per share ­were 5.49 cents against 4.83 cents a year ago. Net cash generated from operating activities was HKD 8,767,000 against HKD 23,377,000 a year ago. The increase in revenue was attributed from Beifushu and Beifuji series 29%; and Pfizer Eye Drops and services provided 11%. The group's sustaining growth performance year-on-year is a proof of clinical acceptance of its products that are well executed by its robust distribution network for sales and marketing activities in the PRC.

Essex Bio-Technology Ltd. to Report First Half, 2014 Results on Aug 07, 2014

Essex Bio-Technology Ltd. announced that they will report first half, 2014 results on Aug 07, 2014

Essex Bio-Technology Ltd., Board Meeting, Aug 07, 2014

Essex Bio-Technology Ltd., Board Meeting, Aug 07, 2014., at 16:00 China Standard Time. Agenda: To consider and approve the interim results of the company and its subsidiaries for the six months ended 30 June 2014; and to consider the payment of an interim dividend, if any.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1061:HK $3.12 HKD -0.07

1061 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1061.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1061 Industry Range
Price/Earnings 30.3x
Price/Sales 4.3x
Price/Book 6.4x
Price/Cash Flow 30.3x
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESSEX BIO-TECHNOLOGY LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at